VNDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vanda Pharmaceuticals Inc (VNDA) is not an immediate buy for a beginner, long-term investor with $50,000-$100,000 available. The stock lacks strong technical indicators, has insider selling pressure, and no recent AI or SwingMax trading signals. While analysts are optimistic about the company's future growth potential, the current financial performance and technical trends do not support an immediate entry point.
The stock's MACD is negative (-0.238) and contracting, indicating bearish momentum. RSI is neutral at 32.051, and moving averages are converging, suggesting indecision. The stock is trading near its support level (S1: 6.978), but there is no clear signal for a reversal or breakout.
Analysts have raised price targets significantly, with multiple Buy ratings citing growth potential from approved drugs like Bysanti and Nereus. The company has a strong pipeline with near-commercial-ready assets and potential $1B opportunities in GLP-1 nausea treatment.
and a weak short-term trend with a 30% chance of minor losses in the next day and month.
In Q4 2025, revenue increased by 7.58% YoY to $57.2M. However, net income remains negative at -$141.19M, despite improving by 2774.33% YoY. EPS also improved to -2.39, but the company is still unprofitable. Gross margin dropped slightly to 90.24%, down 1.74% YoY.
Analysts are bullish, with recent price targets ranging from $7.50 to $24. Key drivers include FDA approvals for Bysanti and Nereus, which are expected to drive significant revenue growth. Analysts anticipate mid-to-high single-digit quarterly growth in prescriptions through 2026.
